NEUROCRINE BIOSCIENCES INC (NBIX) Stock
2 members of Congress disclosed 3 trades in NBIX since 2020: 2 purchases and 1 sale, most recently Lisa McClain (partial sale, Jun 17, 2025). 7 of the hedge funds AlphaScala tracks reported NBIX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $393.68M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Oct 30, 2026.
Which members of Congress traded NEUROCRINE BIOSCIENCES INC (NBIX)?
Most recent: Lisa McClain (partial sale, Jun 17, 2025); records start Dec 21, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-06-17 | partial sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-11 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-12-21 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026.
See all NBIX political trades →Which hedge funds own NBIX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 2.34M | $393.68M | -3% |
| Marshall Wace | 271K | $45.63M | -47% |
| Bridgewater Associates Ray Dalio | 206K | $34.66M | +39% |
| Hussman Investment Trust John Hussman | 27K | $4.60M | +30% |
| Citadel Ken Griffin | 12K | $2.00M | -80% |
| Millennium Management Israel Englander | 12K | $1.95M | -99% |
| D.E. Shaw David Shaw | 6K | $943.6K | -94% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are NEUROCRINE BIOSCIENCES INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 14, 26 | Abernethy Matt | Chief Financial Officer | SELL | 2.3K | $363K |
| Sep 14, 26 | Boyer David W. | Chief Corp. Affairs Officer | SELL | 826 | $130K |
| Sep 9, 26 | Benevich Eric | Chief Commercial Officer | SELL | 2.2K | $333K |
| Jul 28, 26 | Norwalk Leslie V | Director | SELL | 1.3K | $228K |
SEC Form 4 filings as of Oct 30, 2026 · not updated for 4 days; newer filings may exist
See cluster-buy signals across all tickers →NBIX price chart
Powered by TradingViewWhat does NEUROCRINE BIOSCIENCES INC do?
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship product, INGREZZA (valbenazine), a VMAT2 inhibitor, addresses tardive dyskinesia and chorea associated with Huntington's disease, supported by extensive clinical data including long-term efficacy studies and head-to-head pharmacologic comparisons. The company also offers CRENESSITY alongside partnered products like ALKINDI SPRINKLE for adrenal insufficiency, Efemdy for classic congenital adrenal hyperplasia, and collaborations with AbbVie on Orilissa for endometriosis and Oriahnn for uterine fibroids. Neurocrine maintains a robust mid-to-late-stage pipeline featuring investigational therapies such as osavampator for major depressive disorder, direclidine for schizophrenia and bipolar mania, next-generation VMAT2 inhibitors like NBI-1065890 for tardive dyskinesia, and CRF-based programs targeting metabolic conditions including obesity. These efforts underscore its role in advancing therapies for complex movement disorders, psychiatric conditions, and endocrine diseases within the biopharmaceutical sector. Founded in 1992 and headquartered in San Diego, California, Neurocrine Biosciences Inc. plays a pivotal part in neuroscience innovation.